Abstract
Introduction: An open, multi-center, study was designed to address the efficacy and tolerability profile of treatment with escitalopram under naturalistic conditions in outpatients with depression.
Methods: A total of 11,760 patients were treated with escitalopram and followed for 8 weeks. Rating scales included the Clinical Global Impression-Severity (CGI-S), the Clinical Global Impression-Improvement (CGI-I), and a short version of the Montgomery-Åsberg Depression Rating Scale (svMADRS) for assessment of various clinical parameters.
Results: During the course of the study, patients showed a clear pattern of improvement in their general state of health (CGI-S) and a decrease in the severity of their depression. The majority (82.8%) of patients initially received 10 mg/day escitalopram. By the end of the trial period, 32.5% of the patients were treated with 20 mg/day escitalopram compared to 64.0% receiving 10 mg/day escitalopram. After 2 weeks, 40.7% of patients were much or very much improved (CGI-I ≤2), increasing to 82.5% at the last assessment. There were no significant differences in response to treatment between women and men, with regard to treatment by specialists versus GPs, or with regard to age (≤65 versus >65 years of age). Adverse reactions were similar to those found in controlled trials, and no new reactions were noted. The most common adverse reactions were nausea, anxiety, and vertigo.
Conclusions: This observational study corroborates the high therapeutic efficacy of escitalopram treatment, while confirming the tolerability profile, in a naturalistic treatment setting.
Key words
escitalopram - citalopram - major depressive disorder - antidepressants - SSRI - naturalistic - community
References
-
1
Bech P, Andersen HF, Wade A.
Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Pharmacopsychiatry.
2006;
39
128-134
-
2
Boulenger JP, Huusom AKT, Florea I, Bækdal T, Sarchiapone M.
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Curr Med Res Opin.
2006;
22
1331-1341
-
3
Burke WJ, Gergel I, Bose A.
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
J Clin Psychiatry.
2002;
63
331-336
-
4
Chen F, Larsen MB, Sánchez C, Wiborg O.
The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
Eur Neuropsychopharmacol.
2005;
15
193-198
-
5
Colonna L, Reines EH, Andersen HF.
A randomized,double-blind, 24-week study of escitalopram (10 mg/day)versus citalopram (20 mg/day)in primary care patients with major depressive patients with major depressive disorder.
Curr Med Res Opin.
2005;
21
1659-1668
-
6 Fachinformation zu CIPRALEX® 10 mg und CIPRALEX® 20 mg Filmtabletten. Lundbeck GmbH Januar 2004
-
7 Guy W:. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338 1976 Rockville, MD, National Institute of Mental Health
-
8
Kennedy SH, Andersen HF, Lam RW.
Efficacy of escitalopram in the treatment of major depressive disorder: a meta-analysis versus selective serotonin reuptake inhibitors and venlafaxine XR.
J Psychiatry Neuroscience.
2006;
31
122-131
-
9
Lam RW, Andersen HF.
The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.
Pharmacopsychiatry..
2006;
39
180-184
-
10
Lepola UM, Loft H, Reines EH.
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Int Clin Psychopharmacol.
2003;
18
211-217
-
11
Linden M, Ludewig K, Munz T, Dierkes W.
Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: Results of a drug utilization observation study.
Pharmacopsychiatry.
2003;
36
197-205
-
12
Moore N, Verdoux H, Fantino B.
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
Int Clin Psychopharmacol.
2005;
20
131-137
-
13
Möller HJ, Schnitker J.
Einsatz einer modifizierten MADRS bei depressiven Patienten in einer prospektiven Kohortenstudie.
Der Nervenarzt.
2006;
77
((Suppl 2))
S172-S173
-
14
Pedersen AG.
Escitalopram and suicidality in adult depression and anxiety.
Int Clin Psychopharmacol.
2005;
20
139-143
-
15
Rush AJ, Bose A.
Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting.
Depress Anxiety.
2005;
21
26-32
-
16
Sánchez C, Bøgesø K, Ebert B, Heldbo Reines E. et al .
Escitalopram versus Citalopram: the surprising role of the R-enantiomer.
Psychopharmacology.
2004;
174
163-176
-
17
Wade AG, Lemming O, Hedegaard K.
Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care.
Int Clin Psychopharmacol.
2002;
17
95-102
-
18
Zimmerman M, Mattia JI, Posternak MA.
Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?.
Am J Psychiatry.
2002;
159
469-473
Correspondence
H.-J. Möller
Klinikum der Ludwig-Maximilians-Universität München
Klinik für Psychiatrie und Psychotherapie
Nußbaumstraße 7
D-80336 München
Germany
Phone: +49/89/5160 55 01
Fax: +49/89/5160 55 22
Email: Hans-Juergen.Moeller@med.uni-muenchen.de